Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 30, Issue 19, 2012, Pages 2307-2313

  Krop, Ian ^a   Demuth, Tim ^b   Guthrie, Tina ^c   Wen, Patrick Y ^a   Mason, Warren P ^d   Chinnaiyan, Prakash ^e   Butowski, Nicholas ^f   Groves, Morris D ^h   Kesari, Santosh ^g   Freedman, Steven J ⁱ   Blackman, Samuel ^b   Watters, James ^b   Loboda, Andrey ^b   Podtelezhnikov, Alexei ^b   Lunceford, Jared ^b   Chen, Cong ^b   Giannotti, Maxine ^b   Hing, Jeremy ^b   Beckman, Robert ^b   LoRusso, Patricia ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

MK 0752; NOTCH RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; GROWTH INHIBITION; HAIR FOLLICLE; HUMAN; HYPERTRANSAMINASEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUROSURGERY; NEUTROPENIA; NUTRITIONAL DISORDER; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROPIONIC ACIDS; SULFONES; TREATMENT OUTCOME;

EID: 84864005118     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.1540     Document Type: Article

References (22)

1. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature 434:843-850, 2005 (Pubitemid 40558990)
2. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306:269-271, 2004 (Pubitemid 39336870)
3. Phng LK, Gerhardt H: Angiogenesis: A team effort coordinated by notch. Dev Cell 16:196-208, 2009
4. Konishi J, Kawaguchi KS, Vo H, et al: Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67:8051-8057, 2007 (Pubitemid 47395139)
5. Plentz R, Park JS, Rhim AD, et al: Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 136:1741-1749 e6, 2009
6. Fan X, Khaki L, Zhu TS, et al: NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28:5-16, 2010
7. Chen J, Kesari S, Rooney C, et al: Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 1:822-835, 2010
8. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al: C-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20:2096-2109, 2006 (Pubitemid 44157460)
9. Klinakis A, Szabolcs M, Politi K, et al: Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A 103:9262-9267, 2006 (Pubitemid 43902566)
10. Deangelo DJ, Stone RM, Silverman LB, et al: A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/ lymphoma (T-ALL) and other leukemias. J Clin Oncol 24:357s, 2006 (suppl 15; abstr 6585)
11. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997 (Pubitemid 27337928)
12. Blackman SC, Podtelezhnikov A, Railkar RA, et al: Notch pathway inhibition with MK-0752 leads to dose- and time-dependent transcriptional alterations in proliferation, PI3K, and Wnt pathway genes in plucked human hair follicles. Proc Am Assoc for Cancer Res 51:7, 2010 (abstr 26)
13. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
14. Tammam J, Ware C, Efferson C, et al: Downregulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 158:1183-1195, 2009
15. Fre S, Huyghe M, Mourikis P, et al: Notch signals control the fate of immature progenitor cells in the intestine. Nature 435:964-968, 2005 (Pubitemid 40896323)
16. Reference deleted
17. Jiang L, Wu J, Chen Q, et al: Notch1 expression is upregulated in glioma and is associated with tumor progression. J Clin Neurosci 18:387-390, 2011
18. Li J, Cui Y, Gao G, et al: Notch1 is an independent prognostic factor for patients with glioma. J Surg Oncol 103:813-817, 2011
19. Hu YY, Zheng MH, Cheng G, et al: Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer 11:82, 2011
20. Gilbert CA, Daou MC, Moser RP, et al: Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 70:6870-6879, 2010
21. Meng RD, Shelton CC, Li YM, et al: Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69:573-582, 2009
22. Nefedova Y, Sullivan DM, Bolick SC, et al: Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 111:2220-2229, 2008 (Pubitemid 351451536)